CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced the pricing of its public offering of 6,000,000 shares of its common stock at a price of $20.75 per share before underwriting discounts. All of the shares of common stock to be sold in the offering are to be sold by Epizyme. In addition, Epizyme has granted to the underwriters a 30-day option to purchase up to 900,000 additional shares of common stock at the public offering price, less the underwriting discount.
Help employers find you! Check out all the jobs and post your resume.